PRESS RELEASE FROM EXTRAORDINARY GENERAL MEETING IN SCANDINAVIAN CLINICAL NUTRITION I SVERIGE AB (PUBL)

(NGM:SCN)

On December 29, 2008, the Extraordinary General Meeting in SCN decided to approve a divesture of shares in Scandivir AB with 100% majority.

In September, SCN sold 13.5 percent of the company’s total 70-percent holding in Scandivir AB to Anders Uddén, member of the Board of Directors (3,000 shares), and to Carl-Gustav Ingelman, former member of the Board of Directors (10,500 shares), for a total of MSEK 13.5, implying a total value of Scandivir AB at the time of the divesture of MSEK 100. An independent valuation from Strict Corporate Finance, commissioned by the Board of Directors, has confirmed that the divesture of shares has been made on market based conditions.

Scandivir is working with development of diagnostic tests for the obesity virus Ad-36, as well as research around antiviral substances (for example SCN’s patented substance NGNA/N5G) to find treatments for common cold and other virus related diseases. The company was founded in April, 2008 by SCN and the American obesity researcher Professor Richard L. Atkinson, and incorporates an extensive IP portfolio around virus related diseases, of which obesity is one, as well as SCN’s patented antiviral compound NGNA/N5G. Intense R&D work is currently conducted in USA by the Obetech lab staff at the University of Virginia, with support from the company’s network of scientists at Karolinska Institutet in Sweden. The goal is to launch a diagnostic test during 2009, and antiviral treatments soon thereafter.

For more information, please contact:

Carsten Waern, CEO, cw@scnutrition.com, +45 2090 8888

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).For more information, please visit www.scnutrition.com.